Inactivation of CYP2A6 and CYP2A13 during nicotine metabolism

被引:43
|
作者
von Weymarn, LB
Brown, KM
Murphy, SE
机构
[1] Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA
关键词
D O I
10.1124/jpet.105.091306
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Nicotine is the major addictive agent in tobacco. The primary catalyst of nicotine metabolism in humans is CYP2A6. However, the closely related enzyme CYP2A13 is a somewhat better catalyst. CYP2A13 is an extrahepatic enzyme that is an excellent catalyst of the metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamine)- 1-(3- pyridyl)- 1-butanone (NNK). Here we report that both CYP2A6 and CYP2A13 were inactivated during nicotine metabolism. Inactivation of both enzymes was dependent on NADPH and increased with time and concentration. Alternate substrates for CYP2A6 and CYP2A13 protected these enzymes from inactivation. Inactivation of CYP2A13 was irreversible upon extensive dialysis and seems to be mechanism-based. The K-I of CYP2A13 inactivation by nicotine was 17 mu M, the rate of inactivation, k(inact), was 0.1 min(-1), and the t(1/2) was 7 min. However, the loss in enzyme activity occurred after nicotine metabolism was complete, suggesting that a secondary or possible tertiary metabolite of nicotine may be responsible. [5-H-3] Nicotine metabolism by CYP2A13 was monitored by radioflow high-pressure liquid chromatography during the course of enzyme inactivation; the major product was the Delta(1'(5')) iminium ion. However, cotinine was a significant metabolite even at short reaction times. The metabolism of the nicotine Delta 1('(5')) iminium ion to cotinine did not require the addition of aldehyde oxidase. CYP2A13 catalyzed this reaction as well as further metabolism of cotinine to 5'-hydroxycotinine, trans-3'-hydroxycotinine, and N-(hydroxy-methyl)-norcotinine as enzyme inactivation occurred. Studies are on-going to identify the metabolite responsible for nicotine-mediated inactivation of CYP2A13.
引用
收藏
页码:295 / 303
页数:9
相关论文
共 50 条
  • [41] Identification of novel CYP2A6*1B variants:: The CYP2A6*1B allele is associated with faster in vivo nicotine metabolism
    Mwenifumbo, J. C.
    Lessov-Schlaggar, C. N.
    Zhou, Q.
    Kranow, R. E.
    Swan, G. E.
    Benowitz, N. L.
    Tyndale, R. F.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (01) : 115 - 121
  • [42] CYP2A13 MEDIATES THE OXIDATIVE DAMAGE OF NICOTINE ON HUMAN FETAL ADRENAL
    Chen, Man
    Wang, Ting-ting
    Xu, Dan, Jr.
    Guo, Yu
    Li, Xiao-jun
    Wang, Hui
    [J]. DRUG METABOLISM REVIEWS, 2008, 40 : 123 - 123
  • [43] A pilot study characterizing two novel CYP2A6 alleles, CYP2A6*7 and CYP2A6*8, in vivo.
    Xu, C
    Rao, Y
    Xu, B
    Hoffmann, E
    Sellers, EM
    Tyndale, RF
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P35 - P35
  • [44] Synthesis and in vitro Activity of Heterocyclic Inhibitors of CYP2A6 and CYP2A13, Two Cytochrome P450 Enzymes Present in the Respiratory Tract
    Chougnet, Antoinette
    Woggon, Wolf-D.
    Locher, Esther
    Schilling, Boris
    [J]. CHEMBIOCHEM, 2009, 10 (09) : 1562 - 1567
  • [45] Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C
    Ariyoshi, N
    Takahashi, Y
    Miyamoto, M
    Umetsu, Y
    Daigo, S
    Tateishi, T
    Kobayashi, S
    Mizorogi, Y
    Loriot, MA
    Stücker, I
    Beaune, P
    Kinoshita, M
    Kamataki, T
    [J]. PHARMACOGENETICS, 2000, 10 (08): : 687 - 693
  • [46] CYP2A6-and CYP2A13-Catalyzed Metabolism of the Nicotine Δ5′(1′)Iminium Ion
    von Weymarn, Linda B.
    Retzlaff, Cassandra
    Murphy, Sharon E.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2012, 343 (02): : 307 - 315
  • [47] CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people
    Binnington, Matthew J.
    Zhu, Andy Z. X.
    Renner, Caroline C.
    Lanier, Anne P.
    Hatsukami, Dorothy K.
    Benowitz, Neal L.
    Tyndale, Rachel F.
    [J]. PHARMACOGENETICS AND GENOMICS, 2012, 22 (06): : 429 - 440
  • [48] Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans
    Nakajima, M
    Kwon, JT
    Tanaka, N
    Zenta, T
    Yamamoto, Y
    Yamamoto, H
    Yamazaki, H
    Yamamoto, T
    Kuroiwa, Y
    Yokoi, T
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (01) : 72 - 78
  • [49] Functional characterization of CYP2A13 polymorphisms
    Schlicht, K. E.
    Michno, N.
    Smith, B. D.
    Scott, E. E.
    Murphy, S. E.
    [J]. XENOBIOTICA, 2007, 37 (12) : 1439 - 1449
  • [50] Nicotine Metabolism Predicted by CYP2A6 Genotypes in Relation to Smoking Cessation: A Systematic Review
    Jones, Stephanie K.
    Wolf, Bethany J.
    Froeliger, Brett
    Wallace, Kristin
    Carpenter, Matthew J.
    Alberg, Anthony J.
    [J]. NICOTINE & TOBACCO RESEARCH, 2022, 24 (05) : 633 - 642